FR2775187B1 - Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo - Google Patents

Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Info

Publication number
FR2775187B1
FR2775187B1 FR9901903A FR9901903A FR2775187B1 FR 2775187 B1 FR2775187 B1 FR 2775187B1 FR 9901903 A FR9901903 A FR 9901903A FR 9901903 A FR9901903 A FR 9901903A FR 2775187 B1 FR2775187 B1 FR 2775187B1
Authority
FR
France
Prior art keywords
epothilone
antiproliferative
manufacture
composition
pharmaceutical preparation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9901903A
Other languages
English (en)
French (fr)
Other versions
FR2775187A1 (fr
Inventor
Terence O'reilly
Markus Wartmann
Manuel Litchman
Pamela Cohen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9803907.6A external-priority patent/GB9803907D0/en
Priority claimed from GBGB9803905.0A external-priority patent/GB9803905D0/en
Priority claimed from GBGB9805937.1A external-priority patent/GB9805937D0/en
Priority claimed from GBGB9805936.3A external-priority patent/GB9805936D0/en
Priority claimed from US09/233,993 external-priority patent/US6302838B1/en
Application filed by Novartis AG filed Critical Novartis AG
Publication of FR2775187A1 publication Critical patent/FR2775187A1/fr
Application granted granted Critical
Publication of FR2775187B1 publication Critical patent/FR2775187B1/fr
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
FR9901903A 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo Expired - Fee Related FR2775187B1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB9803907.6A GB9803907D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9803905.0A GB9803905D0 (en) 1998-02-25 1998-02-25 Organic compounds
GBGB9805937.1A GB9805937D0 (en) 1998-03-19 1998-03-19 Organic compounds
GBGB9805936.3A GB9805936D0 (en) 1998-03-19 1998-03-19 Organic compounds
US09/233,993 US6302838B1 (en) 1998-02-25 1999-01-19 Cancer treatment with epothilones

Publications (2)

Publication Number Publication Date
FR2775187A1 FR2775187A1 (fr) 1999-08-27
FR2775187B1 true FR2775187B1 (fr) 2003-02-21

Family

ID=27517450

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9901903A Expired - Fee Related FR2775187B1 (fr) 1998-02-25 1999-02-16 Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo

Country Status (10)

Country Link
US (4) US6635666B2 (https=)
EP (1) EP1056453B1 (https=)
JP (1) JP2002504511A (https=)
AU (1) AU755944B2 (https=)
BE (1) BE1011980A5 (https=)
CA (1) CA2319752A1 (https=)
FR (1) FR2775187B1 (https=)
IT (1) ITMI990375A1 (https=)
NZ (1) NZ506187A (https=)
WO (1) WO1999043320A1 (https=)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4183099B2 (ja) 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6867305B2 (en) 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
US6365749B1 (en) 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
US20020058286A1 (en) * 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
AU3606600A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for prostate cancer
AU3606700A (en) * 1999-02-26 2000-09-14 Napro Biotherapeutics, Inc. Treatment regimen for hormone-sensitive cancers
US20050042275A1 (en) * 1999-08-04 2005-02-24 Jean-Claude Sonntag Epothilone compositions
US6414015B1 (en) 2000-01-28 2002-07-02 Utah State University Laulimalide microtubule stabilizing agents
US6518421B1 (en) 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
UA75365C2 (en) 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
WO2002058699A1 (en) * 2001-01-25 2002-08-01 Bristol-Myers Squibb Company Pharmaceutical forms of epothilones for oral administration
EE200300323A (et) * 2001-01-25 2003-10-15 Bristol-Myers Squibb Company Epotilooni analoogi sisaldav parenteraalne ravimpreparaat, meetod selle valmistamiseks ning kasutamine
ES2304240T3 (es) 2001-01-25 2008-10-01 Bristol-Myers Squibb Company Procedimientos para la preparacion de preparaciones farmaceuticas que contienen analogos de epotilona para el tratamiento de cancer.
MXPA03006412A (es) * 2001-01-25 2003-10-15 Bristol Myers Squibb Co Metodos para administrar analogos de epotilona para tratamiento de cancer.
CN1774253A (zh) * 2001-02-20 2006-05-17 布里斯托尔-迈尔斯斯奎布公司 用环氧丙酯酮衍生物治疗顽固性肿瘤
KR20040028720A (ko) 2001-02-20 2004-04-03 브리스톨-마이어스스퀴브컴파니 치료불응성 종양 치료용 에포틸론 유도체
IL157443A0 (en) 2001-03-14 2004-03-28 Bristol Myers Squibb Co Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
AU2002251067B2 (en) * 2001-03-19 2005-05-26 Novartis Ag Combinations comprising an antidiarrheal agent and an epothilone or an epothilone derivative
MXPA03010909A (es) 2001-06-01 2004-02-17 Bristol Myers Squibb Co Derivados de epotilona.
AU2008203233B2 (en) * 2001-07-19 2010-04-29 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TWI315982B (en) * 2001-07-19 2009-10-21 Novartis Ag Combinations comprising epothilones and pharmaceutical uses thereof
TW200408407A (en) * 2001-11-30 2004-06-01 Dana Farber Cancer Inst Inc Methods and compositions for modulating the immune system and uses thereof
TWI287986B (en) * 2001-12-13 2007-10-11 Novartis Ag Use of Epothilones for the treatment of the carcinoid syndrome
JP5384777B2 (ja) * 2001-12-18 2014-01-08 有限会社大長企画 強筋肉剤、抗炎症剤
MXPA04006822A (es) 2002-01-14 2004-12-08 Novartis Ag Combinaciones que comprenden epotilonas y anti-metabolitos.
EP1340498A1 (en) * 2002-03-01 2003-09-03 Schering Aktiengesellschaft Use of epothilones in the treatment of brain diseases associated with proliferative processes
AU2003218107A1 (en) 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C12-cyano epothilone derivatives
TW200403994A (en) 2002-04-04 2004-03-16 Bristol Myers Squibb Co Oral administration of EPOTHILONES
DE10217254A1 (de) * 2002-04-15 2003-10-23 Proteosys Ag Verwendung von Substanzen zur Behandlung von Tumoren
TW200400191A (en) 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
WO2003105828A1 (en) 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
US6921769B2 (en) 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP2186811A1 (en) * 2002-08-23 2010-05-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
AU2003275068B2 (en) 2002-09-23 2009-09-17 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone B, and X-Ray crystal structures of epothilone B
CA2501610C (en) * 2002-10-11 2012-01-03 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
BR0317150A (pt) * 2002-12-09 2005-11-01 Novartis Ag Estabilizadores de microtúbulos em stents para o tratamento de estenose
US20040146632A1 (en) * 2003-01-23 2004-07-29 Cristina Sayman Effective multi-component penetrating and flavoring marinade
BRPI0412000A (pt) * 2003-06-27 2006-08-15 Novartis Ag tratamento de cáncer com epotilonas
AU2004268377B2 (en) * 2003-09-02 2008-06-26 Novartis Ag Cancer treatment with epothilones
GB0405898D0 (en) 2004-03-16 2004-04-21 Novartis Ag Organic compounds
EP1640004A1 (en) * 2004-09-24 2006-03-29 Schering Aktiengesellschaft Use of epothilones in the treatment of bone metastases and bone tumors or cancers
AR052142A1 (es) * 2004-11-18 2007-03-07 Bristol Myers Squibb Co Perla recubierta enterica que comprende ixabepilona, y preparacion y administracion de la misma
EP1824458A1 (en) * 2004-11-18 2007-08-29 Bristol-Myers Squibb Company Enteric coated bead comprising epothilone or an epothilone analog, and preparation and administration thereof
JO2596B1 (en) * 2004-11-30 2011-02-27 نوفارتيس ايه جي Compositions include epothelones and tyrosine protein kinase inhibitors and their pharmaceutical uses
US20060121511A1 (en) 2004-11-30 2006-06-08 Hyerim Lee Biomarkers and methods for determining sensitivity to microtubule-stabilizing agents
DE102005008309A1 (de) * 2005-02-17 2006-08-24 Schering Ag Pharmazeutische Mittel enthaltend fluoralkylhaltige Metallkomplexe und Epothilone
CN101415420B (zh) * 2006-04-05 2012-09-05 诺瓦提斯公司 用于治疗癌症的治疗剂的组合
EP2997973A1 (en) * 2006-11-15 2016-03-23 Dana-Farber Cancer Institute, Inc. Stabalized maml peptides and uses thereof
EP2170473A1 (en) 2007-06-20 2010-04-07 Saluc Technologie S.A. Convertible dining / billiard table
EP2065054A1 (en) 2007-11-29 2009-06-03 Bayer Schering Pharma Aktiengesellschaft Combinations comprising a prostaglandin and uses thereof
EP2070521A1 (en) 2007-12-10 2009-06-17 Bayer Schering Pharma Aktiengesellschaft Surface-modified nanoparticles
DE102007059752A1 (de) 2007-12-10 2009-06-18 Bayer Schering Pharma Aktiengesellschaft Funktionalisierte, feste Polymernanopartikel enthaltend Epothilone
US9175047B2 (en) 2009-01-14 2015-11-03 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2210584A1 (en) 2009-01-27 2010-07-28 Bayer Schering Pharma Aktiengesellschaft Stable polymeric composition comprising an epothilone and an amphiphilic block copolymer
WO2014116594A1 (en) * 2013-01-23 2014-07-31 The University Of Toledo Highly selective anti-cancer agents targeting non-small cell lung cancer and other forms of cancer
US10059741B2 (en) 2015-07-01 2018-08-28 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP3475418A4 (en) * 2016-06-28 2020-03-04 Alma Mater Studiorum -Universita' di Bologna TATK-CDKL5 FUSION PROTEINS, COMPOSITIONS, FORMULATIONS AND THEIR USE

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US142990A (en) * 1873-09-23 Improvement in machines for burnishing the shanks of boots and shoes
US34452A (en) * 1862-02-18 Improvement in railroad joints or chairs
US203938A (en) * 1878-05-21 Improvement in wire fences
US203876A (en) * 1878-05-21 Improvement in piston water-meters
US220295A (en) * 1879-10-07 Improvement in hinges
US260098A (en) * 1882-06-27 Rolls for longitudinally slitting railroad-rails
US127432A (en) * 1872-06-04 Improvement in tuckers for sewing-machines
US176429A (en) * 1876-04-25 Improvement in nut-locks
US87634A (en) * 1869-03-09 Improvement in grain-storehouses
US253697A (en) * 1882-02-14 John halley and alexandee baee
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5716939A (en) * 1993-07-15 1998-02-10 Pfizer Inc. Amide derivatives of 16-membered ring antibiotic macrolides
JP4183099B2 (ja) * 1995-11-17 2008-11-19 ゲゼルシャフト・フュア・ビオテヒノロジッシェ・フォルシュング・ミット・ベシュレンクテル・ハフツング（ゲー・ベー・エフ） エポチロンｃおよびｄ、製造法ならびに組成物
US5969145A (en) * 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
AU716610B2 (en) 1996-08-30 2000-03-02 Novartis Ag Method for producing epothilones, and intermediate products obtained during the production process
ES2312695T3 (es) 1996-11-18 2009-03-01 Gesellschaft Fur Biotechnologische Forschung Mbh (Gbf) Epotilones e y f.
US6515016B2 (en) 1996-12-02 2003-02-04 Angiotech Pharmaceuticals, Inc. Composition and methods of paclitaxel for treating psoriasis
US6204388B1 (en) * 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
CA2273083C (en) * 1996-12-03 2012-09-18 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US6441186B1 (en) * 1996-12-13 2002-08-27 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) * 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19720312A1 (de) * 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
TR200002299T2 (tr) * 1998-02-05 2000-11-21 Novartis Ag Epotilon kompozisyonları.
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) * 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
NZ508326A (en) 1998-06-18 2003-10-31 Novartis Ag A polyketide synthase and non ribosomal peptide synthase genes, isolated from a myxobacterium, necessary for synthesis of epothiones A and B
US6121029A (en) * 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
WO1999067253A2 (en) 1998-06-22 1999-12-29 Novartis Ag Desmethyl epothilones
WO2000000485A1 (de) 1998-06-30 2000-01-06 Schering Aktiengesellschaft Epothilon-derivate, verfahren zu deren herstellung, zwischenprodukte und ihre pharmazeutische verwendung
DE19848306A1 (de) * 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
WO2000031247A2 (en) 1998-11-20 2000-06-02 Kosan Biosciences, Inc. Recombinant methods and materials for producing epothilone and epothilone derivatives
US6780620B1 (en) * 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
DK1652926T3 (da) 2000-04-28 2010-02-15 Kosan Biosciences Inc Krystallinsk epothilon D
JP3977411B2 (ja) * 2004-03-10 2007-09-19 株式会社クレハ アミン系塩基性化合物とその用途

Also Published As

Publication number Publication date
EP1056453B1 (en) 2010-10-06
WO1999043320A1 (en) 1999-09-02
US6635666B2 (en) 2003-10-21
FR2775187A1 (fr) 1999-08-27
JP2002504511A (ja) 2002-02-12
AU2927999A (en) 1999-09-15
EP1056453A1 (en) 2000-12-06
BE1011980A5 (fr) 2000-03-07
AU755944B2 (en) 2003-01-02
NZ506187A (en) 2003-11-28
CA2319752A1 (en) 1999-09-02
US20060223867A1 (en) 2006-10-05
US7091226B2 (en) 2006-08-15
ITMI990375A1 (it) 1999-08-25
US20040024033A1 (en) 2004-02-05
US7875601B2 (en) 2011-01-25
US20050165071A1 (en) 2005-07-28
US20020028839A1 (en) 2002-03-07

Similar Documents

Publication Publication Date Title
FR2775187B1 (fr) Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
MA26790A1 (fr) Composition dietetique ou pharmaceutique a l'usage pour la prevention ou le traitement de la hyper-oxalurie
FR2733684B1 (fr) Utilisation de retinoides dans une composition cosmetique ou pour la fabrication d'une composition pharmaceutique
EP0602317A3 (de) Bandage für das Kniegelenk.
FR2780281B1 (fr) Compositions comprenant des nanopigments d'oxydes de fer pour la coloration artificielle de la peau et utilisations
DZ2494A1 (fr) Composition pharmaceutique d'oméprazole.
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
BRPI9810519B1 (pt) derivados de 4''-substituìdo-9-desoxo-9a-aza-9a-homoeritromicina a e composição farmacêutica compreendendo os mesmos.
MA26507A1 (fr) Compositions pharmaceutiques d'aerosol
EP1450863A4 (en) PROCESS FOR IMAGING VESSELS WITH NANOTEHTIC CONTAINERS
EP1279959A4 (en) POLYMER COMPOSITION FOR FORMING SURFACES FOR BIOSENSORS
FR2722681B1 (fr) Calecon pour homme
FR2749589B1 (fr) Composition d'enrobage et utilisations dans l'industrie alimentaire et dans l'industrie pharmaceutique
FR2783517B1 (fr) Nouveaux derives de l'acide 10-hyroxy-2-decenoique et utilisation dans une composition destinee a favoriser la desquamation de la peau, et composition le comprenant
FR2708201B1 (fr) Utilisation de dérivés d'acétamide pour la fabrication de médicaments.
IT1304008B1 (it) Dispositivo per l'eliminazione di ratti e simili.
FR2781148B1 (fr) Composition cosmetique comprenant des pigments et un agent antitranspirant, utilisation d'une telle composition
FR2728783B1 (fr) Prothese d'articulation metatarso-phalangienne totale du premier rayon du pied
EE05317B1 (et) Etinl”stradiooli ja drospirenooni sisaldav farmatseutiline kompositsioon kasutamiseks rasestumisvastase vahendina
FR2714603B1 (fr) Composition dermatologique et son utilisation pour la préparation d'un médicament.
FR2720628B1 (fr) Prothèse pour l'articulation trapézo-métacarpienne.
MD283F1 (ro) Compozitie de ingrediente pentru balsamul tonifiant "legenda"
FR2643643B1 (fr) Compositions utilisables pour la preparation de membranes d'etancheite et membranes obtenues
FR2780427B1 (fr) Poutre mixte bois-beton pour la construction et l'ouvrage d'art
FR2722991B1 (fr) Utilisation de la beta2-glycoproteine i sous au moins une de ses formes comme agent anti-infectueux et composition pharmaceutique corrrespondante

Legal Events

Date Code Title Description
ST Notification of lapse

Effective date: 20141031